Close

Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results

Go back to Deutsche Says Anacor (ANAC) Tavaborole Numbers are Solid, Hinges on 2nd Phase 3 Results

Canaccord Genuity Trims PT on Anacor Pharmaceuticals (ANAC), Keeps Buy

January 30, 2013 10:09 AM EST

Canaccord Genuity lowered its price target on Anacor Pharmaceuticals (NASDAQ: ANAC) from $9 to $5 but is keeping a Buy rating following phase 3 data on Tavaborole.

The firm comments, "Maintaining BUY but lowering target to $5 from $9 as tavaboroles potential in onychomycosis becomes... More

Anacor Pharma (ANAC) Reports Positive P-3 Data on Tavaborole for Onychomycosis

January 29, 2013 7:10 AM EST

Anacor Pharmaceuticals (NASDAQ: ANAC) today announced positive preliminary results from the first of two Phase 3 trials of tavaborole, its topical anti-fungal for onychomycosis, a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States. Tavaborole achieved a high... More